CD274 and colorectal cancer: To understand the resistance mechanism of colorectal cancer patients to immune checkpoint therapies, we administrated anti-PD-L1 therapy to two commonly used pMMR/MSI-L murine colorectal tumor models CT26 and MCA38 [34, 35].